- Home
- YGMZ vs ONVO Comparison
YGMZ vs ONVO Comparison
Compare YGMZ & ONVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YGMZ
- ONVO
- Stock Information
- Founded
- YGMZ 2002
- ONVO 2007
- Country
- YGMZ China
- ONVO United States
- Employees
- YGMZ N/A
- ONVO N/A
- Industry
- YGMZ Transportation Services
- ONVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- YGMZ Consumer Discretionary
- ONVO Health Care
- Exchange
- YGMZ Nasdaq
- ONVO Nasdaq
- Market Cap
- YGMZ 7.0M
- ONVO 6.5M
- IPO Year
- YGMZ 2020
- ONVO N/A
- Fundamental
- Price
- YGMZ $0.86
- ONVO $0.39
- Analyst Decision
- YGMZ
- ONVO
- Analyst Count
- YGMZ 0
- ONVO 0
- Target Price
- YGMZ N/A
- ONVO N/A
- AVG Volume (30 Days)
- YGMZ 124.8K
- ONVO 243.5K
- Earning Date
- YGMZ 01-01-0001
- ONVO 02-06-2025
- Dividend Yield
- YGMZ N/A
- ONVO N/A
- EPS Growth
- YGMZ N/A
- ONVO N/A
- EPS
- YGMZ N/A
- ONVO N/A
- Revenue
- YGMZ $55,805,416.00
- ONVO $103,000.00
- Revenue This Year
- YGMZ N/A
- ONVO $59.08
- Revenue Next Year
- YGMZ N/A
- ONVO $18.24
- P/E Ratio
- YGMZ N/A
- ONVO N/A
- Revenue Growth
- YGMZ N/A
- ONVO N/A
- 52 Week Low
- YGMZ $0.68
- ONVO $0.32
- 52 Week High
- YGMZ $6.24
- ONVO $1.74
- Technical
- Relative Strength Index (RSI)
- YGMZ 44.05
- ONVO 47.81
- Support Level
- YGMZ $0.68
- ONVO $0.34
- Resistance Level
- YGMZ $0.85
- ONVO $0.51
- Average True Range (ATR)
- YGMZ 0.09
- ONVO 0.06
- MACD
- YGMZ -0.01
- ONVO -0.00
- Stochastic Oscillator
- YGMZ 40.23
- ONVO 30.00
About YGMZ MingZhu Logistics Holdings Limited
MingZhu Logistics Holdings Ltd is a Holding company. Its business activities include trucking services and car owner services. Its segments are the trucking business, car owner services business, and liquor distribution business. It generates the majority of its revenue from the trucking segment.
About ONVO Organovo Holdings Inc.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.